Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden
The STROKESTOP II study is a proposed study to determine if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.
https://clinicaltrials.gov/ct2/show/NCT02743416?term=STROKESTOP&rank=1
http://www.strokestop2.se